- Home
- JBTM vs HALO Comparison
JBTM vs HALO Comparison
Compare JBTM & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBTM | HALO |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JBTM | HALO |
|---|---|---|
| Price | $153.85 | $62.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $161.50 | $73.33 |
| AVG Volume (30 Days) | 468.6K | ★ 2.4M |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | N/A | ★ 4.74 |
| Revenue | ★ $3,257,800,000.00 | $1,242,852,000.00 |
| Revenue This Year | $124.13 | $34.83 |
| Revenue Next Year | $4.37 | $24.84 |
| P/E Ratio | ★ N/A | $13.14 |
| Revenue Growth | ★ 92.43 | 31.19 |
| 52 Week Low | $90.08 | $46.26 |
| 52 Week High | $156.46 | $79.50 |
Technical Indicators
Market Signals| Indicator | JBTM | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 34.09 |
| Support Level | $136.92 | $61.23 |
| Resistance Level | $156.46 | $63.26 |
| Average True Range (ATR) | 4.13 | 2.42 |
| MACD | 1.59 | -0.79 |
| Stochastic Oscillator | 91.32 | 7.60 |
Price Performance
Historical ComparisonAbout JBTM JBT Marel Corporation
JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.